Amgen to acquire Horizon Therapeutics for US$26.4 Billion
"The California-based biotech leader will pay $116.50 for each share of Horizon, according to Reuters. Struck just three weeks before the close of 2022, it is biopharma’s largest deal of the year."
"Rumors of a potential acquisition first started circulating last month, after WSJbroke the story. At the time, the company confirmed it was fielding offers from three industry giants - Amgen, Sanofi and Janssen - though discussions were still “highly preliminary.”
https://www.biospace.com/article/amgen-to-buy-horizon-in-biotech-s-biggest-deal-of-2022-/